AbbVie (NYSE:ABBV) Stock Jumps 1.2% – Still a Buy?

AbbVie Inc. (NYSE:ABBV)’s stock price rose 1.2% during mid-day trading on Monday. The company traded as high as $267.34 and last traded at $265.9260. 7,495,570 shares were traded during trading, an increase of 16% from the average daily volume of 6,440,094 shares. The stock had previously closed at $262.82.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: The FDA granted two Breakthrough Therapy Designations for AbbVie’s investigational telisotuzumab adizutecan (Temab-A) in colorectal cancer and non-small cell lung cancer. The designations strengthen AbbVie’s antibody-drug conjugate portfolio and could accelerate regulatory discussions if clinical results remain positive. AbbVie Temab-A Breakthrough Therapy Designations
• Positive Sentiment: AbbVie and Genmab reported that epcoritamab plus R-CHOP reduced the risk of progression or death by 51% versus R-CHOP alone in newly diagnosed diffuse large B-cell lymphoma. The Phase 3 win supports potential expansion of Epkinly into frontline treatment and positions the combination as a possible competitor to Roche’s Polivy, with regulatory discussions planned. Epcoritamab Phase 3 DLBCL Results
• Positive Sentiment: Scotiabank raised its AbbVie price target from $280 to $320 and maintained a “sector outperform” rating, implying further potential upside. The broader analyst consensus remains equivalent to a Buy, although ratings are not guarantees of performance. Scotiabank Raises AbbVie Price Target
• Neutral Sentiment: AbbVie is scheduled to report third-quarter results later this month. Investors will focus on Humira replacement growth, newer immunology and oncology products, and whether full-year guidance is maintained.
• Negative Sentiment: AbbVie lowered third-quarter 2026 adjusted EPS guidance to $3.73–$3.77 from the prior outlook of $3.85, citing $216 million of acquired in-process research and development and milestone expenses. Full-year adjusted EPS guidance was also reduced to $13.76–$13.96.
• Negative Sentiment: One analysis highlighted a payout ratio above 190%, raising questions about the sustainability of AbbVie’s dividend if earnings do not improve or special expenses continue. The stock’s elevated valuation also leaves less room for disappointment.

Analyst Upgrades and Downgrades

ABBV has been the subject of several research reports. Sanford C. Bernstein restated a “market perform” rating and set a $225.00 price objective (up from $203.00) on shares of AbbVie in a research report on Tuesday, June 23rd. BMO Capital Markets boosted their target price on shares of AbbVie from $258.00 to $300.00 and gave the stock an “outperform” rating in a report on Monday, July 13th. Argus increased their target price on shares of AbbVie from $250.00 to $270.00 in a research note on Tuesday, August 4th. UBS Group restated a “neutral” rating on shares of AbbVie in a report on Tuesday. Finally, Scotiabank increased their price objective on AbbVie from $280.00 to $320.00 and gave the company an “outperform” rating in a research report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $273.82.

AbbVie Price Performance

The firm has a market cap of $471.11 billion, a price-to-earnings ratio of 75.32, a price-to-earnings-growth ratio of 1.20 and a beta of 0.24. The stock’s fifty day moving average price is $258.12 and its 200-day moving average price is $235.42.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Friday, July 31st. The company reported $3.65 EPS for the quarter, topping analysts’ consensus estimates of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The firm had revenue of $16.99 billion during the quarter, compared to analyst estimates of $16.80 billion. During the same quarter last year, the business posted $2.97 EPS. The company’s revenue was up 10.2% on a year-over-year basis. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, equities research analysts predict that AbbVie Inc. will post 14.05 EPS for the current fiscal year.

AbbVie Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be given a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 2.6%. The ex-dividend date of this dividend is Thursday, October 15th. AbbVie’s dividend payout ratio (DPR) is 195.48%.

Insider Buying and Selling at AbbVie

In related news, EVP Nicholas Donoghoe sold 32,710 shares of the company’s stock in a transaction on Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the transaction, the executive vice president directly owned 74,430 shares of the company’s stock, valued at approximately $18,607,500. The trade was a 30.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.06% of the company’s stock.

Hedge Funds Weigh In On AbbVie

Several institutional investors and hedge funds have recently bought and sold shares of ABBV. Juncture Wealth Strategies LLC lifted its position in shares of AbbVie by 451.0% in the third quarter. Juncture Wealth Strategies LLC now owns 9,559 shares of the company’s stock worth $2,500,000 after purchasing an additional 7,824 shares in the last quarter. Congress Asset Management Co. increased its stake in AbbVie by 262.7% in the 3rd quarter. Congress Asset Management Co. now owns 12,173 shares of the company’s stock valued at $3,184,000 after buying an additional 8,817 shares during the period. Colton Groome Financial Advisors LLC increased its stake in AbbVie by 50.2% in the 3rd quarter. Colton Groome Financial Advisors LLC now owns 8,274 shares of the company’s stock valued at $2,165,000 after buying an additional 2,767 shares during the period. Legacy Private Trust Co. lifted its position in AbbVie by 0.6% in the 3rd quarter. Legacy Private Trust Co. now owns 33,361 shares of the company’s stock worth $8,727,000 after buying an additional 210 shares in the last quarter. Finally, Tompkins Financial Corp boosted its stake in shares of AbbVie by 0.4% during the 3rd quarter. Tompkins Financial Corp now owns 35,524 shares of the company’s stock valued at $9,293,000 after buying an additional 156 shares during the period. Hedge funds and other institutional investors own 70.23% of the company’s stock.

AbbVie Company Profile

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health.

The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.